170 likes | 179 Views
This collaborative research initiative aims to visualize and analyze prostate cancer testing and outcomes data to uncover insights, support medical decisions, and identify new breakthroughs. Partnerships with top institutions worldwide are accelerating this research. Join the global real-world evidence network and be a part of this collaborative analytics initiative.
E N D
Stockholm, May 23 2017 Amy Leval, Outcomes Research Manager, Med DrEpidemiologi, Janssen Forskningssamverkan–olikamodeller
Interactive Visualization- Visualizing Prostate Cancer Testing and Outcomes -
Who are we? Olof Akre Urologist Professor KI olof.akre@ki.se Markus Aly Urologist, Ph.D. Karolinska University Hospital Markus.Aly@ki.se Sandra Eloranta Researcher Med. Sci. KI sandra.eloranta@ki.se Amy Leval Researcher Janssen aleval@ITS.JNJ.com Johan Liwing RWE Partnerships Janssen jliwing@its.jnj.com Mario Romero Visualization Professor KTH marior@kth.se To be continued…
OHDSI community •>140 researcher institutions in academia, industry, government, health systems • Common data model (OMOP) •>20 countries •>660 million patients
Collaborativeanalytics – currentpossibility, future standard? 11 data sources, 4 countries, 250 million patients Common data modell. Dela på protokoll, analysresultat, inte på individdata!
Janssen’s global real world evidence network By analyzing a broader range of parameters, real world evidence research can uncover outcomes, unmet needs and clues to future medical breakthroughs. Janssen is partnering with top institutions world wide to accelerate this new line of research. Our network aims to: Apply scientific best practices Advance methodologies Generate evidence about disease pathways, healthcare delivery, and the effects of medical interventions Support medical decisions and identify new medical breakthroughs Sweden Hungary Korea USA Taiwan Canada
Unique opportunity for Nordic life science 10% Of all global real world evidence research originates from Sweden. Other Nordic countries are also generating an extensive proportion. Real world evidence will impact all phases of medical research and therapeutic development. Thanks to its data infrastructure, the Nordic region can become a hot-spot for advanced medical research by enabling uniquely comprehensive and long term studies. Janssen is partnering with KarolinskaInstitutet in a major collaborative research initiative that focuses on: Treatment resistant depression Prostate cancer Psoriasis B-Cell malignancies Methodology development Janssen’s real world evidence network also facilitates collaboration in other disease areas, across Nordic institutions.
Broad collaboration: Johnson & Johnson Innovation + Karolinska Institutet Launched 22 May 2015 • A broad and unique industry-academia collaboration in the Nordic region to: • advance medical research • nurture emerging healthcare companies • accelerate development of breakthrough products for improved treatment outcomes • To support the collaborationJohnson & Johnson Innovation opened a life science innovation office at Karolinska Institutet. Commercial knowledge Resources Coaching Investment Seed-financing Innovation focus (KI Innovations AB) Abundance of early-stage science World class life sciences research Nordic influence • Academic excellence • Prestige • History
“IMI is the world's biggest public-private partnership (PPP) in the life sciences. Through the IMI 2 programme, it has a €3.3 billion budget for the period 2014-2024.”
Samverkan – topp 3 checklista 1.Förståelse kring den vetenskapliga frågeställningen 2.Uppskatta kompetens hos olika team - ta in mer extern kompetens vid behov… 3.Kontrakt, och tid för kontrakt och process
Samverkan för att utveckla life science Det finns flera modeller